Determinants of Liver Metastasis

肝转移的决定因素

基本信息

  • 批准号:
    10558473
  • 负责人:
  • 金额:
    $ 178.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-21 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

PROGRAM TITLE: Determinants of Liver Metastasis PROGRAM ABSTRACT Liver metastasis indicates a terminal illness for many cancers and is a leading cause of cancer death in the United States. There is currently no integrated research program devoted to mechanisms of liver metastasis. While common in certain cancer types (such as pancreas and colon), metastasis is less common but highly malignant in other cancer types (such as prostate cancer). The long-term goal of our Program is to understand and address the shared and unique drivers of liver metastasis in colon, pancreas, and prostate primary tumor types. Published work and preliminary data from the four integrated projects point to key roles for four critical molecular signaling axes in mediating liver metastasis, through mechanisms likely common across many primary tumor types. To complement this mechanistic expertise, this Program assembles clinical expertise across different tumor types and liver microenvironment models. Together, this collaborative Program investigates the hypothesis that normal liver tissue is inherently suppressive of metastatic tumor expansion, unless alterations in the liver microenvironment result in the loss of metastatic suppressors. Project 1 explores the acquisition of features that enable metastasis from circulating saturated fat and subsequent endoglin signaling in hepatocytes and cancer epithelia. The pro-metastatic impact of hepatic stellate cell (HSC)-derived hyaluronic acids in non-alcoholic fatty liver disease is examined in Project 2. Thought to activate pro-cancer phenotypes of HSCs and macrophages, Project 3 investigates the regulation and contribution of yes-associated protein (YAP) and downstream signaling pathways to create a pro-metastatic liver microenvironment. Project 4 investigates the roles of methionine adenosyltransferase (MAT) proteins in liver metastasis, from the loss of protective MAT1A to the pro-cancer elevated expression of MAT2A and MAT2B. By examining these four intersecting signaling pathways and comparing findings across models, this Program will augment current understanding of factors in the liver microenvironment and tumor that permit the development of liver metastases. This Program unites essential expertise in the fields of liver and cancer pathobiology to represent the first multi- investigator effort focused on common mechanisms involved in liver metastasis from disparate tumor models (prostate, colon, and pancreas). The Program adopts a unique approach, investigating the role of the normal liver microenvironment and leveraging each project team’s substantial expertise along with essential resources, including pharmacologic means of addressing the signaling axes, partnerships with healthcare providers to validate the findings in animal models through human tissue specimens, and innovative technology to isolate and analyze metastatic factors including circulating tumor cells and extracellular vesicles. Successful completion of the Program will establish new paradigms in liver metastasis and test novel therapeutic strategies.
项目标题:肝转移的决定因素

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Neil A. Bhowmick其他文献

First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
  • DOI:
    10.1007/s40265-022-01683-6
  • 发表时间:
    2022-02-17
  • 期刊:
  • 影响因子:
    14.400
  • 作者:
    Jacob J. Adashek;Joshua J. Breunig;Edwin Posadas;Neil A. Bhowmick;Leigh Ellis;Stephen J. Freedland;Hyung Kim;Robert Figlin;Jun Gong
  • 通讯作者:
    Jun Gong
603: Prostate Androgen Responsiveness Involve Stromal Transforming Growth Factor-Beta Signaling
  • DOI:
    10.1016/s0022-5347(18)37865-0
  • 发表时间:
    2004-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Neil A. Bhowmick;Susan Kasper
  • 通讯作者:
    Susan Kasper
413: The Conditional Knock-Out of Transforming Growth Factor-Beta Signaling in the Prostate Stroma Results in Prostate Intraepithelial Neoplasia
  • DOI:
    10.1016/s0022-5347(18)37675-4
  • 发表时间:
    2004-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Neil A. Bhowmick;Harold L. Moses
  • 通讯作者:
    Harold L. Moses
CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer
CD105阻断可恢复耐药的表皮生长因子受体(EGFR)突变型非小细胞肺癌对奥希替尼的敏感性
  • DOI:
    10.1016/j.drup.2025.101237
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    21.700
  • 作者:
    Manish Thiruvalluvan;Sandrine Billet;Zhenqiu Liu;Joseph Lownik;Barliz Waissengrin;Hyoyoung Kim;Anton L. Villamejor;Larry Milshteyn;Xiamo Li;Matthew Gayhart;Manuel Araña;Kamya Sankar;Edwin M. Posadas;Jean Lopategui;Sungyong You;Karen L. Reckamp;Neil A. Bhowmick
  • 通讯作者:
    Neil A. Bhowmick
171: Expression of Dominant Active Transforming Growth Factor-Beta Receptor in Fetal Rat Bladder Stromal Cells
  • DOI:
    10.1016/s0022-5347(18)37433-0
  • 发表时间:
    2004-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jeffrey M. Donohoe;John C. Pope;Neil A. Bhowmick;Mark C. Adams;John W. Brock;Simon W. Hayward
  • 通讯作者:
    Simon W. Hayward

Neil A. Bhowmick的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Neil A. Bhowmick', 18)}}的其他基金

Determinants of Liver Metastasis
肝转移的决定因素
  • 批准号:
    10701208
  • 财政年份:
    2022
  • 资助金额:
    $ 178.45万
  • 项目类别:
Determinants of Liver Metastasis
肝转移的决定因素
  • 批准号:
    10295701
  • 财政年份:
    2021
  • 资助金额:
    $ 178.45万
  • 项目类别:
Project 1- Role of fat in metastatic engraftment and expansion in the liver
项目 1 - 脂肪在肝脏转移植入和扩张中的作用
  • 批准号:
    10807146
  • 财政年份:
    2020
  • 资助金额:
    $ 178.45万
  • 项目类别:
Determinants of Liver Metastasis
肝转移的决定因素
  • 批准号:
    10524071
  • 财政年份:
    2020
  • 资助金额:
    $ 178.45万
  • 项目类别:
Project 1- Role of fat in metastatic engraftment and expansion in the liver
项目 1 - 脂肪在肝脏转移植入和扩张中的作用
  • 批准号:
    10558474
  • 财政年份:
    2020
  • 资助金额:
    $ 178.45万
  • 项目类别:
Project 1- Role of fat in metastatic engraftment and expansion in the liver
项目 1 - 脂肪在肝脏转移植入和扩张中的作用
  • 批准号:
    10331757
  • 财政年份:
    2020
  • 资助金额:
    $ 178.45万
  • 项目类别:
Determinants of Liver Metastasis
肝转移的决定因素
  • 批准号:
    10895782
  • 财政年份:
    2020
  • 资助金额:
    $ 178.45万
  • 项目类别:
Determinants of Liver Metastasis
肝转移的决定因素
  • 批准号:
    10738332
  • 财政年份:
    2020
  • 资助金额:
    $ 178.45万
  • 项目类别:
Determinants of Liver Metastasis
肝转移的决定因素
  • 批准号:
    10331756
  • 财政年份:
    2020
  • 资助金额:
    $ 178.45万
  • 项目类别:
The paradoxical roles of beta hydroxy butyrate in the liver pro-metastatic niche
β-羟基丁酸在肝脏促转移生态位中的矛盾作用
  • 批准号:
    10745869
  • 财政年份:
    2020
  • 资助金额:
    $ 178.45万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 178.45万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了